Skip to main
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Medline is well-positioned to continue its dominance in the US market and expand internationally, capitalizing on its strong relationships with customers, diverse product offerings, and efficient logistics capabilities. Additionally, the company's consistent financial performance and strong cash flow generation provide stability and support for future growth initiatives. The recent IPO is expected to provide additional capital for expansion and innovation, further strengthening Medline's competitive position in the industry.

Bears say

Medline is a dominant player in the US medical-surgical market, with strong relationships with major health systems and a vertically-integrated supply chain. However, the company's focus on consolidation and automation may lead to a decline in long-term profitability and a struggle to adapt to changing market trends and customer needs. Additionally, Medline's aggressive M&A strategy and its high reliance on rented assets may pose financial risks and limit its ability to generate significant economic profit in the future.

Medline Inc (MDLN) has been analyzed by 24 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 24 analysts, Medline Inc (MDLN) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.